Regulation of adipose tissue metabolism in cancer cachexia

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 11, Issue 3, 2008, Pages 201-207

  Bing, Chen ^a   Trayhurn, Paul ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Adipose tissue; Cachexia; Cancer; Lipid metabolism; Mediators of fat loss; Zinc 2 glycoprotein

Indexed keywords

ADIPOCYTOKINE; ALPHA2 GLYCOPROTEIN; TUMOR NECROSIS FACTOR ALPHA; ZINC;

ADIPOCYTE; ADIPOSE TISSUE; APPETITE; ATROPHY; CACHEXIA; CELL MATURATION; ENERGY METABOLISM; HOMEOSTASIS; HUMAN; LIPID METABOLISM; LIPID STORAGE; LIPOLYSIS; MEDIATOR; NEOPLASM; REVIEW; TISSUE METABOLISM;

ADIPOCYTES; ADIPOSE TISSUE; CACHEXIA; ENERGY METABOLISM; HUMANS; LIPID METABOLISM; LIPOLYSIS; NEOPLASMS; WASTING SYNDROME;

EID: 42149118391     PISSN: 13631950     EISSN: 15353885     Source Type: Journal    
DOI: 10.1097/MCO.0b013e3282f948e2     Document Type: Review

References (58)

1. Skipworth RJC, Stewart GD, Dejong CHC, et al. Pathophysiology of cancer cachexia: much more than host-tumour interaction? Clin Nutr 2007; 83:667-676. A review on the pathogenesis of cancer cachexia particularly the patient factors in addition to the interactions between the host and the tumour.
2. Morley JE, Thomas DR, Wilson MM. Cachexia: pathophysiology and clinical relevance. Am J Clin Nutr 2006; 83:735-743.
3. Slaviero KA, Read JA, Clarke SJ, Rivory LP. Baseline nutritional assessment in advanced cancer patients receiving palliative chemotherapy. Nutr Cancer 2003; 46:148-157.
4. Tisdale MJ. Molecular pathways leading to cancer cachexia. Physiology (Bethesda) 2005; 20:340-348.
5. Perboni S, Inui A. Anorexia in cancer: role of feeding-regulatory peptides. Philos Trans R Soc Lond B Biol Sci 2006; 361:1281-1289.
6. Chance WT, Xiao C, Dayal R, Sheriff S. Alteration of NPY and Y1 receptor in dorsomedial and ventromedial areas of hypothalamus in anorectic tumor-bearing rats. Peptides 2007; 28:295-301. The work suggests dysfunction of NPY feeding systems in experimental cancer anorexia.
7. Marks DL, Ling N, Cone RD. Role of the central melanocortin system in cachexia. Cancer Res 2001; 61:1432-1438.
8. Bing C, Taylor S, Tisdale MJ, Williams G. Cachexia in MAC16 adenocarcinoma: suppression of hunger despite normal regulation of leptin, insulin and hypothalamic neuropeptide Y. J Neurochem 2001; 79:1004-1012.
9. Wolf I, Sadetzki S, Kanety H, et al. Adiponectin, ghrelin, and leptin in cancer cachexia in breast and colon cancer patients. Cancer 2006; 106:966-973.
10. Johnen H, Lin S, Kuffner T, et al. Tumor-induced anorexia and weight loss are mediated by the TGF-beta superfamily cytokine MIC-1. Nat Med 2007; 13:1333-1340. This study demonstrated that serum MIC-1 correlates with cancer cachexia in patients, and this is due to its anorexic action mediated by hypothalamic neuropeptides and signal transduction. The findings suggest that MIC-1 is a newly defined central regulator of appetite and a potential target for the treatment of cancer cachexia.
11. Jatoi A, Daly BD, Hughes VA, et al. Do patients with nonmetastatic nonsmall cell lung cancer demonstrate altered resting energy expenditure? Ann Thorac Surg 2001; 72:348-351.
12. Ravasco P, Monteiro-Grillo I, Camilo M. Colorectal cancer: intrinsic characteristics modulate cancer energy expenditure and the risk of cachexia. Cancer Invest 2007; 25:308-314. Describes a longitudinal study on resting energy expenditure in colorectal cancer patients.
13. Bing C, Brown M, King P, et al. Increased gene expression of brown fat uncoupling protein (UCP)1 and skeletal muscle UCP2 and UCP3 in MAC16-induced cancer cachexia. Cancer Res 2000; 60:2405-2410.
14. Shellock FG, Riedinger MS, Fishbein MC. Brown adipose tissue in cancer patients: possible cause of cancer-induced cachexia. J Cancer Res Clin Oncol 1986; 111:82-85.
15. Collins P, Bing C, McCulloch P, Williams G. Muscle UCP-3 mRNA levels are elevated in weight loss associated with gastrointestinal adenocarcinoma in humans. Br J Cancer 2002; 86:372-375.
16. Trayhurn P, Wood IS. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 2004; 92:347-355.
17. Trayhurn P, Bing C. Appetite and energy balance signals from adipocytes. Philos Trans R Soc Lond B Biol Sci 2006; 361:1237-1249.
18. Rosen ED, Spiegelman BM. Adipocytes as regulators of energy balance and glucose homeostasis. Nature 2006; 444:847-853.
19. Ogiwara H, Takahashi S, Kato Y, et al. Diminished visceral adipose tissue in cancer cachexia. J Surg Oncol 1994; 57:129-133.
20. Fouladiun M, Korner U, Bosaeus I, et al. Body composition and time course changes in regional distribution of fat and lean tissue in unselected cancer patients on palliative care - correlations with food intake, metabolism, exercise capacity, and hormones. Cancer 2005; 103:2189-2198.
21. Fearon KC, Preston T. Body composition in cancer cachexia. Infusionstherapie 1990; 17 (Suppl 3):63-66.
22. Kalantar-Zadeh K, Horwich TB, Oreopoulos A, et al. Risk factor paradox in wasting diseases. Curr Opin Clin Nutr Metab Care 2007; 10:433-442. A comprehensive review on the paradox of conventional risk factors related to better survival in wasting syndromes, which has clinical importance regarding intervention strategies.
23. Halabi S, Ou SS, Vogelzang NJ, Small EJ. Inverse correlation between body mass index and clinical outcomes in men with advanced castration-recurrent prostate cancer. Cancer 2007; 110:1478-1484. This clinical study shows that a higher BMI is associated with better survival in patients with metastatic castration-recurrent prostate cancer; hence it identifies an obesity paradox in cancer patients.
24. Bing C, Russell S, Becket E, et al. Adipose atrophy in cancer cachexia: morphologic and molecular analysis of adipose tissue in tumour-bearing mice. Br J Cancer 2006; 95:1028-1037.
25. Zuijdgeest-van Leeuwen SD, van den Berg JW, Wattimena JL, et al. Lipolysis and lipid oxidation in weight-losing cancer patients and healthy subjects. Metabolism 2000; 49:931-936.
26. Agustsson T, Ryden M, Hoffstedt J, et al. Mechanism of increased lipolysis in cancer cachexia. Cancer Res 2007; 67:5531-5537. This study found significantly increased lipolysis in isolated adipocytes in cancer patients with cachexia, and this is attributable to enhanced expression and activity of hormone-sensitive lipase. Thus, inhibition of this enzyme may prevent or reverse fat loss in cancer patients.
27. Thompson MP, Cooper ST, Parry BR, Tuckey JA. Increased expression of the mRNA for hormone-sensitive lipase in adipose tissue of cancer patients. Biochim Biophys Acta 1993; 1180:236-242.
28. Thompson MP, Koons JE, Tan ET, Grigor MR. Modified lipoprotein lipase activities, rates of lipogenesis, and lipolysis as factors leading to lipid depletion in C57BL mice bearing the preputial gland tumor, ESR-586. Cancer Res 1981; 41:3228-3232.
29. Dessi S, Batetta B, Spano O, et al. Perturbations of triglycerides but not of cholesterol metabolism are prevented by antitumour necrosis factor treatment in rats bearing an ascites hepatoma (Yoshida AH-130). Br J Cancer 1995; 72:1138-1143.
30. Yoshikawa T, Noguchi Y, Satoh S, et al. Insulin resistance and the alterations of glucose transporter-4 in adipose cells from cachectic tumor-bearing rats. JPEN J Parenter Enteral Nutr 1997; 21:347-349.
31. Cerami A, Ikeda Y, Le Trang N, et al. Weight loss associated with an endotoxin-induced mediator from peritoneal macrophages: the role of cachectin (tumor necrosis factor). Immunol Lett 1985; 11:173-177.
32. Plomgaard P, Fischer CP, Ibfelt T, et al. TNF-alpha modulates human in vivo lipolysis. J Clin Endocrinol Metab 2007; doi:10.1210/jc.2007-1761. This study demonstrated that infusion of a relatively low dose of recombinant human TNFα induces systemic lipolysis in healthy individuals without affecting skeletal muscle lipid metabolism. The finding suggests that TNFα may play a role in the mediation of dyslipidemia in chronic disease.
33. Yang JY, Koo JH, Yoon HY, et al. Effect of scopoletin on lipoprotein lipase activity in 3T3-L1 adipocytes. Int J Mol Med 2007; 20:527-531. Reports that TNFα-induced suppression of LPL activity can be partially reversed by scopoletin.
34. Ryden M, Arner P. Tumour necrosis factor-alpha in human adipose tissue - from signalling mechanisms to clinical implications. J Intern Med 2007; 262:431-438. A detailed review on the role of TNFα in human white fat, particularly its regulation of lipolysis, an important metabolic event in adipocytes since it links to body fat mass and insulin resistance.
35. Hammarstedt A, Isakson P, Gustafson B, et al. Wnt-signaling is maintained and adipogenesis inhibited by TNFa but not MCP-1 and resistin. Biochem Biophys Res Commun 2007; 357:700-706. The study suggests that TNFα acts on Wnt-signaling to inhibit adipogenesis.
36. Cawthorn WP, Heyd F, Hegyi K, et al. Tumour necrosis factor-alpha inhibits adipogenesis via a beta-catenin/TCF4(TCF7L2)-dependent pathway. Cell Death Differ 2007; 14:1361-1373. This study illustrated the mechanisms underlying inhibitory effect of TNFα on adipocyte differentiation. The data suggest that TNFα-induced antiadipogenesis is via a Wnt/beta-catenin/TCF4-dependent pathway.
37. Lagathu C, Yvan-Charvet L, Bastard JP, et al. Long-term treatment with interleukin-1beta induces insulin resistance in murine and human adipocytes. Diabetologia 2006; 49:2162-2173.
38. Kayacan O, Karnak D, Beder S, et al. Impact of TNF-alpha and IL-6 levels on development of cachexia in newly diagnosed NSCLC patients. Am J Clin Oncol 2006; 29:328-335.
39. Iwase S, Murakami T, Saito Y, Nakagawa K. Steep elevation of blood interleukin-6 (IL-6) associated only with late stages of cachexia in cancer patients. Eur Cytokine Netw 2004; 15:312-316.
40. Fortunati N, Manti R, Birocco N, et al. Pro-inflammatory cytokines and oxidative stress/antioxidant parameters characterize the bio-humoral profile of early cachexia in lung cancer patients. Oncol Rep 2007; 18:1521-1527. This paper reported a significant increase in serum TNFa, and oxidative stress/antioxidant parameters in lung cancer patients with cachexia, suggesting that the bio-humoral profile could be used for the early diagnosis and follow-up of the syndrome.
41. Maltoni M, Fabbri L, Nanni O, et al. Serum levels of tumour necrosis factor alpha and other cytokines do not correlate with weight loss and anorexia in cancer patients. Support Care Cancer 1997; 5:130-135.
42. Trujillo ME, Sullivan S, Harten I, et al. Interleukin-6 regulates human adipose tissue lipid metabolism and leptin production in vitro. J Clin Endocrinol Metab 2004; 89:5577-5582.
43. Zaki MH, Nemeth JA, Trikha M. CNTO 328, a monoclonal antibody to IL-6, inhibits human tumor-induced cachexia in nude mice. Int J Cancer 2004; 111:592-595.
44. Richey LM, George JR, Couch ME, et al. Defining cancer cachexia in head and neck squamous cell carcinoma. Clin Cancer Res 2007; 13:6561-6567. The authors identified that in addition to T(4) status, elevated C-reactive protein and decreased hemoglobin, increased serum IL-6 is associated with cancer cachexia in patients with head and neck squamous cell carcinoma.
45. Krzystek-Korpacka M, Matusiewicz M, Diakowska D, et al. Impact of weight loss on circulating IL-1, IL-6, IL-8, TNF-alpha, VEGF-A, VEGF-C and midkine in gastroesophageal cancer patients. Clin Biochem 2007; 40:1353-1360. Report that upregulation of IL-6 and IL-8 may contribute to the development of cachexia in gastroesophageal malignancies.
46. Kuroda K, Nakashima J, Kanao K, et al. Interleukin 6 is associated with cachexia in patients with prostate cancer. Urology 2007; 69:113-117. This study found that high levels of serum IL-6 was associated with low serum total protein, cholesterol and hemoglobin levels, and reduced BMI, but increased mortality rate in prostate cancer patients.
47. Jan V, Cervera P, Maachi M, et al. Altered fat differentiation and adipocytokine expression are inter-related and linked to morphological changes and insulin resistance in HIV-1-infected lipodystrophic patients. Antivir Ther 2004; 9:555-564.
48. Diez-Itza I, Sanchez LM, Allende MT, et al. Zn-alpha 2-glycoprotein levels in breast cancer cytosols and correlation with clinical, histological and biochemical parameters. Eur J Cancer 1993; 29A:1256-1260.
49. Hale LP, Price DT, Sanchez LM, et al. Zinc alpha-2-glycoprotein is expressed by malignant prostatic epithelium and may serve as a potential serum marker for prostate cancer. Clin Cancer Res 2001; 7:846-853.
50. Bondar OP, Barnidge DR, Klee EW, et al. LC-MS/MS Quantification of Zn-{alpha}2 Glycoprotein: a potential serum biomarker for prostate cancer. Clin Chem 2007; 53:673-678. This paper describes a high-flow liquid chromatography-tandem mass spectrometry method for measuring serum ZAG concentrations, and reported that circulating ZAG are increased in patients with prostate cancer.
51. Todorov PT, McDevitt TM, Meyer DJ, et al. Purification and characterization of a tumor lipid-mobilizing factor. Cancer Res 1998; 58:2353-2358.
52. Hirai K, Hussey HJ, Barber MD, et al. Biological evaluation of a lipid-mobilizing factor isolated from the urine of cancer patients. Cancer Res 1998; 58:2359-2365.
53. Bing C, Russell ST, Beckett EE, et al. Expression of uncoupling proteins-1, -2 and -3 mRNA is induced by an adenocarcinoma-derived lipid-mobilizing factor. Br J Cancer 2002; 86:612-618.
54. Russell ST, Hirai K, Tisdale MJ. Role of beta3-adrenergic receptors in the action of a tumour lipid mobilizing factor. Br J Cancer 2002; 86:424-428.
55. Bing C, Bao Y, Jenkins J, et al. Zinc-alpha2-glycoprotein, a lipid mobilizing factor, is expressed in adipocytes and is up-regulated in mice with cancer cachexia. Proc Natl Acad Sci USA 2004; 101:2500-2505.
56. Bao Y, Bing C, Hunter L, et al. Zinc-alpha2-glycoprotein, a lipid mobilizing factor, is expressed and secreted by human (SGBS) adipocytes. FEBS Lett 2005; 579:41-47.
57. Dahlman I, Kaaman M, Olsson T, et al. A unique role of monocyte chemoattractant protein 1 among chemokines in adipose tissue of obese subjects. J Clin Endocrinol Metab 2005; 90:5834-5840.
58. Rolli V, Radosavljevic M, Astier V, et al. Lipolysis is altered in MHC class I zinc-alpha(2)-glycoprotein deficient mice. FEBS Lett 2007; 581:394-400. The authors developed knockout mice for zinc-alpha2-glycoprotein and demonstrated the functional significance of the protein in the regulation of body fat. Their work has shown that mice without the protein are susceptible to weight gain on a high-fat diet, probably due to a marked reduction in lipolysis.